Figure 1.
The flow chart of selecting patients with AML for this study and their composition based on WHO-HAEM5 and ICC classifications. (A) The flowchart outlining the eligibility criteria for the study. (B) The overlapping cases between the WHO and ICC classifications, demonstrating the flow of the study cohort within the 2 classifications. ∗APL with PML::RARA (4), AML with RUNX1::RUNX1T1 fusion (8), AML with CBFB::MYH11 fusion (17), AML with DEK::NUM214 fusion (2), AML with KMT2A rearrangement (16), AML with MECOM rearrangement (13), AML with NPM1 mutation (150), AML with CEBPA mutation (21), AML with BCR::ABL1 fusion (3), AML with other defined alterations (3).

The flow chart of selecting patients with AML for this study and their composition based on WHO-HAEM5 and ICC classifications. (A) The flowchart outlining the eligibility criteria for the study. (B) The overlapping cases between the WHO and ICC classifications, demonstrating the flow of the study cohort within the 2 classifications. ∗APL with PML::RARA (4), AML with RUNX1::RUNX1T1 fusion (8), AML with CBFB::MYH11 fusion (17), AML with DEK::NUM214 fusion (2), AML with KMT2A rearrangement (16), AML with MECOM rearrangement (13), AML with NPM1 mutation (150), AML with CEBPA mutation (21), AML with BCR::ABL1 fusion (3), AML with other defined alterations (3).

Close Modal

or Create an Account

Close Modal
Close Modal